This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Obesity and atypical antipsychotic drugs

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • weight gain with antipsychotic therapy is important as a risk factor for cardiovascular events and the development of type 2 diabetes mellitus, and because it may undermine adherence to treatment
  • some patients gain substantial weight during treatment with atypical antipsychotics
    • weight gain appears to be commonest and greatest with clozapine and olanzapine; moderate with risperidone, sertindole and zotepine; and probably least with ami-sulpride and aripiprazole
    • weight gain is difficult to predict in the individual, but possible predictors include a good clinical response to treatment, an initial body mass index below 23kg/m2, and younger age
  • the possibility of weight gain needs to be discussed with the patient before starting treatment. Ideally, a drug with a low tendency to increase weight is a better choice for a patient who is already obese or prone to weight fluctuations (1)
  • clinicians should measure the patients' weight, height and body mass index before starting, and at intervals throughout, treatment

Reference:

  1. Drug and Therapeutics Bulletin (2004); 42(8):57-60.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page